CTI BioPharma (CTIC) : Analyst Rating Update

CTI BioPharma (CTIC) : 3 analysts are covering CTI BioPharma (CTIC) and their average rating on the stock is 3.67, which is read as a Sell. A Zacks Investment Research rank of 2, which recommends a Buy affirms that they expect a large upside in the stock from the current levels. However, 1 analysts consider that the stock has more downward risks ahead, hence, they suggest a Strong Sell on the stock. A total of 2 brokerage firms believe that the stock is fairly valued, hence they advise a Hold on the stock.

CTI BioPharma (CTIC) : Currently there are 2 street experts covering CTI BioPharma (CTIC) stock. The most bullish and bearish price target for the stock is $5 and $1 respectively for the short term. The average price target of all the analysts comes to $2.88. The estimated standard deviation from the target is $3.01.

CTI BioPharma (NASDAQ:CTIC): The stock opened at $0.33 on Wednesday but the bulls could not build on the opening and the stock topped out at $0.36 for the day. The stock traded down to $0.33 during the day, due to lack of any buying support eventually closed down at $0.34 with a loss of -0.50% for the day. The stock had closed at $0.34 on the previous day. The total traded volume was 864,209 shares.

The company shares have dropped -81.72% from its 1 Year high price. On Jul 14, 2015, the shares registered one year high at $1.99 and the one year low was seen on Feb 10, 2016. The 50-Day Moving Average price is $0.41 and the 200 Day Moving Average price is recorded at $0.66.

CTI BioPharma Corp. (CTI), formerly Cell Therapeutics, Inc., is a biopharmaceutical company focused on the acquisition, development and commercialization of targeted therapies covering a spectrum of blood-related cancers that offer a benefit to patients and healthcare providers. The Company is focused on commercializing PIXUVRI (pixantrone), or PIXUVRI, in the European Union, for the treatment of adult patients with multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (NHL), and conducting a Phase III clinical trial program of pacritinib for the treatment of adult patients with myelofibrosis to support regulatory submission for approval in the United States and Europe. It is also engaged in evaluating pacritinib in earlier clinical trials as treatment for other blood-related cancers. Its development product candidates include tosedostat and Opaxio.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.